Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition

Diabetes Care

Volumn 38, Issue 9, 2015, Pages 1687-1693

  Peters, Anne L ^a   Buschur, Elizabeth O ^b   Buse, John B ^c   Cohan, Pejman ^d   Diner, Jamie C ^c   Hirsch, Irl B ^e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d Specialized Endocrine Care Center   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CANAGLIFLOZIN; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; EMPAGLIFLOZIN; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; ANION GAP; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED STUDY; DIABETIC KETOACIDOSIS; DISEASE ASSOCIATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUGLYCEMIC DIABETIC KETOACIDOSIS; FEMALE; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; MALE; MEDICAL HISTORY; MIDDLE AGED; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; TREATMENT DURATION; UNITED STATES; VOMITING; AGED; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2;

ADULT; AGED; BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84962339296     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0843     Document Type: Article

References (23)

1. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011; 378:182-197.
2. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2015;38:412-419.
3. Lamos EM, Younk LM, Davis SN. Empagliflozin, a sodiumglucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs 2014;23:875-882.
4. Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014;37:1480-1483.
5. Cherney DZI, Perkins BA, Soleymanlou N, et al. Renalhemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129: 587-597.
6. Rosenstock J, Cefalu WT, Lapuerta P, et al. Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. Diabetes Care 2015;38:431-438.
7. Powell DR, DaCosta CM, Smith M, et al. Effect of LX4211 on glucose homeostasis and body composition in preclinical models. J Pharmacol Exp Ther 2014;350:232-242.
8. Bell DS. Case reports that illustrate the efficacy of SGLT2 inhibitors in the type 1 diabetic patient. Case Rep Endocrinol 2015;2015:676191.
9. Weinstock RS, Xing D, Maahs DM, et al.; T1D Exchange Clinic Network. Severe hypoglycemia and DKA in adults with T1D: results from the T1D exchange clinic registry. J Clin Endocrinol Metab 2013;98:3411-3419.
10. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009;32:1335-1343.
11. Munro JF, Campbell IW, McCuish AC, Duncan LJP. Euglycaemic diabetic ketoacidosis. BMJ 1973;2:578-580.
12. McGuire LC, Cruickshank AM, Munro PT. Alcoholic ketoacidosis. Emerg Med J 2006;23: 417-420.
13. Umpierrez GE, DiGirolamo M, Tuvlin JA, Isaacs SD, Bhoola SM, Kokko JP. Differences inmetabolic and hormonalmilieu in diabetic- And alcoholinduced ketoacidosis. J Crit Care 2000;15:52-59.
14. Hayami T, Kato Y, Kamiya H, et al. Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a lowcarbohydrate diet. J Diabetes Invest. 20 February 2015 [Epub ahead of print]. DOI:10.1111/jdi.12330.
15. Hilaire R, Costello H. Prescriber beware: report of adverse effect of sodium-glucose cotransporter 2 inhibitor use in a patient with contraindication. Am J Emerg Med 2015:33:604.e3-e4.
16. Ireland JT, Thomson WS. Euglycemic diabetic ketoacidosis. BMJ 1973;3:107.
17. Yabe D, Nishikino R, Kaneko M, Iwasaki M, Seino Y. Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events. Expert Opin Drug Saf 2015;14:795-800.
18. Groop LC, Bonadonna RC, DelPrato S, et al. Glucose and free fatty acid metabolism in noninsulin- dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 1989;84:205-213.
19. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124:499-508.
20. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014;124:509-514.
21. Keller U, Schnell H, Sonnenberg GE, Gerber PPG, Stauffacher W. Role of glucagon in enhancing ketone body production in ketotic diabetic man. Diabetes 1983;32:387-391.
22. FDA Drug Safety Communication. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Available from http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm?source=govdelivery&utm-medium=email&utm-source=govdelivery. Accessed 15 May 2015.
23. Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med 2006;144:350-357.